Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - HUMANIGEN, INCv427431_ex99-1.htm



Washington, D.C. 20549






Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): December 17, 2015


KaloBios Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)


Delaware   001-35798   77-0557236
(State or other Jurisdiction of
  (Commission File No.)  

(IRS Employer Identification No.)



442 Littlefield Avenue

South San Francisco, CA 94080

(Address of principal executive offices, including zip code)


(650) 243-3100

(Registrant’s telephone number, including area code)


(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):


  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On December 17, 2015, Martin Shkreli was terminated as Chief Executive Officer and resigned as a member of the board of directors of KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) (the “Company”). In addition, on December 17, 2015, Tony Chase resigned from the Company’s Board of Directors and from its Audit Committee. There were no disagreements with the Company that led to the resignations of Mr. Shkreli and Mr. Chase.


The Company’s press release announcing the foregoing is attached as Exhibit 99.1 hereto.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits.


Number Description
99.1 Press Release, dated December 21, 2015







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  KaloBios Pharmaceuticals, Inc.
  By: /s/ Christopher Thorn  
    Name: Christopher Thorn
Title:   Interim Chief Financial Officer


Dated: December 21, 2015